Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 258

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 258
---
   |     | Kadimastem   
 (Historical) |           |   |     | Pro         
 Forma       
 Combined(2) |            |   |
|:------------------------------------------------------------------------|:----|:-------------|----------:|:--|:----|:-------------|----------:|:--|:----|:------------|-----------:|:--|
| Book value per share(1)                                                 |     | $            |     (8.84 | ) |     | $            |     (0.52 | ) |     | $           |       0.28 |   |
| Weighted average outstanding shares (basic and diluted)                 |     |              | 1,048,632 |   |     |              | 4,193,689 |   |     |             | 26,746,852 |   |
| Weighted average loss per share (basic and diluted)                     |     | $            |     (1.94 | ) |     | $            |     (0.03 | ) |     | $           |      (0.11 | ) |

____________ (1)Book value per share is calculated using the formula: total shareholders’ equity from the balance sheet as of June 30, 2024 divided by shares outstanding as of June 30, 2024. (2)The pro forma combined numbers include the adjustments according to Kadimastem’s and NLS’s Unaudited Pro Forma Condensed Combined Balance Sheets as presented in this proxy statement/prospectus on page 191.

129 NLS BUSINESS NLS is a clinical -stagebiopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex CNS disorders with unmet medical needs. NLS’s lead compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary extended -release, or ER formulation, is being developed for the treatment of narcolepsy (lead indication) and ADHD (follow -onindication). NLS believes that this dual mechanism of action will also enable mazindol ER to provide potential therapeutic benefit in other rare and complex CNS disorders. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders. However, treatment options for these conditions are often limited, inadequate or nonexistent, and the development of new CNS treatments generally trails behind other therapeutic areas. NLS is pursuing the development of the next generation of CNS